carriers (Ma-DB-NLC) topical gel was formulated for skin cancer treatment. DOX is a potent
anticancer drug that was combined with BBR to synergize the clinical efficacy of the
formulation in skin cancer treatment. The findings of the in-silico study indicated that DOX &
BBR were the promising ligands of DNA-Topoisomerase-Ⅱ & p13k, with excellent docking
scores. The central composite rotatable design (CCRD) was used to optimize the NLC …